Dementia

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

Thursday, July 29, 2021 - 7:59am

This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).

Key Points: 
  • This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).
  • This new designation completes the quartet of orphan designations for VO659 in HD and SCA in both the US and EU.
  • Patients affected by Huntington's disease experience motor disturbances, personality changes and dementia, leading to increasing disability, loss of independence and reduced survival.
  • VICO's antisense oligonucleotide platform (AON) is focusing on different forms of spinocerebellar ataxia (SCA) and Huntington Disease (HD).

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

Thursday, July 29, 2021 - 7:57am

This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).

Key Points: 
  • This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA).
  • This new designation completes the quartet of orphan designations for VO659 in HD and SCA in both the US and EU.
  • Patients affected by Huntington's disease experience motor disturbances, personality changes and dementia, leading to increasing disability, loss of independence and reduced survival.
  • VICO's antisense oligonucleotide platform (AON) is focusing on different forms of spinocerebellar ataxia (SCA) and Huntington Disease (HD).

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Wednesday, July 28, 2021 - 8:00am

Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Wednesday, July 28, 2021 - 8:00am

LAUSANNE, Switzerland and SAN FRANSICO, July 28, 2021 /PRNewswire/ -- Asceneuron SA, a clinical-stage biotech company dedicated to targeting the root cause of neurodegenerative diseases, is pleased to announce that Chief Executive Officer, Dirk Beher has been invited to present at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies during the prestigious Alzheimer's Association International Conference which takes place between the 26 – 30 July 2021 in Denver, USA and online. The talk will take place on Wednesday, 28 July at 08:00am MDT / 4:00pm CET.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.
  • The Peter Davies Memorial Symposium: The Future of Tau Based Therapies (preclinical, early phase, current studies, future)

Global Dementia Cases Forecasted To Triple By 2050

Tuesday, July 27, 2021 - 3:00pm

DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.

Key Points: 
  • DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
  • Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
  • They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
  • The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.

Memory Health Receives Third Patent For Role In The Prevention And/Or Treatment Of Neurodegenerative Disease

Tuesday, July 27, 2021 - 3:00pm

The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.

Key Points: 
  • The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.
  • Memory Health is the only supplement patented specifically for the prevention and/or treatment of neurodegenerative disease.
  • The term Neurodegenerative disease describes a range of conditions such as memory loss, mild cognitive impairment, dementia, and Alzheimer's disease, primarily affecting the neurons in the human brain.
  • Memory Health is the gold standard of brain supplementation, the only patented formula for the prevention and/or treatment of neurodegenerative disease, especially dementia, in human subjects.

Global Dementia Cases Forecasted To Triple By 2050

Tuesday, July 27, 2021 - 3:00pm

DENVER, July 27, 2021 /PRNewswire/ -- Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050. Meanwhile, anticipated trends in smoking, high body mass index and high blood sugar are predicted to increase prevalence by nearly the same number: 6.8 million cases. Both according to new global prevalence data reported at the Alzheimer's Association International Conference® (AAIC®) 2021 in Denver and virtually.

Key Points: 
  • DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
  • Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
  • They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
  • The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.

BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

Tuesday, July 27, 2021 - 1:00pm

BioVie has obtained authorization from the U.S. Food & Drug Administration to initiate a pivotal Phase 3 trial of NE3107 in Alzheimers Disease called the NM101 study ( NCT04669028 ).

Key Points: 
  • BioVie has obtained authorization from the U.S. Food & Drug Administration to initiate a pivotal Phase 3 trial of NE3107 in Alzheimers Disease called the NM101 study ( NCT04669028 ).
  • NM101 is a randomized double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate Alzheimers Disease.
  • At the AAIC this year there are literally hundreds of presentations on inflammation and Alzheimers disease and dozens on insulin resistance and AD.
  • NE3107 is the first potentially disease modifying, anti-inflammatory insulin sensitizer therapy in a phase 3 trial, said Cuong Do, Chief Executive Officer of BioVie.

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

Monday, July 26, 2021 - 9:10pm

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • Leveraging the experience gained from the development and marketing of a treatment for Alzheimers disease, Eisai aims to establish the Eisai Dementia Platform.
  • Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Monday, July 26, 2021 - 1:00pm

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.

Key Points: 
  • These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.
  • The OVERTURE study demonstrated that gamma frequency neuro-modulation led to a significant reduction in brain atrophy in AD patients.
  • Accelerated brain atrophy is associated with cognitive decline and loss of function in AD patients and is a driver of mortality and morbidity in Alzheimers disease progression.
  • Cognito Therapeutics is a clinical-stage neuro-physiology company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimers disease.